This study is testing a medicine called **Rezpegaldesleukin** (Rezpeg) for adults with moderate to severe **atopic dermatitis** (AD), a skin condition that causes itchy, inflamed skin. The study will last about a year, with the first part being 15-35 days of checking if you can join, and then up to 378 days of treatment and follow-up. The medicine being tested is a form of a protein called **interleukin-2**, which might help reduce the symptoms of AD. The study is **double-blind**, meaning neither you nor the doctors will know if you are getting Rezpeg or a placebo (a fake treatment) to ensure fair results.

• To join, you must be 18-70 years old and have had AD for over a year, with a specific severity level.
• You cannot participate if you’ve used certain immune treatments recently or have other health issues like HIV or hepatitis.
• If part of the study, you will need to have frequent check-ups and follow study rules strictly.